Header

UZH-Logo

Maintenance Infos

Delivering Precision Medicine in Oncology Today and in Future-The Promise and Challenges of Personalised Cancer Medicine: a position paper by the European Society for Medical Oncology (ESMO)


Ciardiello, F; Arnold, D; Casali, P G; Cervantes, A; Douillard, J-Y; Eggermont, A; Eniu, A; McGregor, K; Peters, S; Piccart, M; Popescu, R; Van Cutsem, E; Zielinski, C; Stahel, R (2014). Delivering Precision Medicine in Oncology Today and in Future-The Promise and Challenges of Personalised Cancer Medicine: a position paper by the European Society for Medical Oncology (ESMO). Annals of Oncology, 25(9):1673-1678.

Abstract

Although the description and interpretation of cancer genetics has been at the core of cancer research for more than a century, in this decade genomic medicine is set to profoundly transform every aspect of cancer care. Already, the anecdotal cases of individuals who have not responded to conventional chemotherapy but for whom whole genome sequencing has identified a gene target for directed therapy with remarkable clinical effect [1], point to a time in the not-too-distant future when cancer genome sequencing will be a routine adjunct to the clinico-pathological 'work-up' of a newly diagnosed cancer. For now, the identification of genes central to cancer biology is generating highly relevant diagnostic, prognostic and therapeutic information that has already translated to the clinic. The extraordinary pace of change is set to continue. The new era of personalised cancer medicine will touch every aspect of cancer care-from patient counselling, to cancer diagnosis, tumour classification, treatment and outcome-that demands a new level of in-depth education and collaboration between researchers, cancer specialists, patients and other stakeholders. In this position paper, ESMO sets out the current status in the field of personalised cancer medicine and addresses issues and challenges for the medical oncology community.

Abstract

Although the description and interpretation of cancer genetics has been at the core of cancer research for more than a century, in this decade genomic medicine is set to profoundly transform every aspect of cancer care. Already, the anecdotal cases of individuals who have not responded to conventional chemotherapy but for whom whole genome sequencing has identified a gene target for directed therapy with remarkable clinical effect [1], point to a time in the not-too-distant future when cancer genome sequencing will be a routine adjunct to the clinico-pathological 'work-up' of a newly diagnosed cancer. For now, the identification of genes central to cancer biology is generating highly relevant diagnostic, prognostic and therapeutic information that has already translated to the clinic. The extraordinary pace of change is set to continue. The new era of personalised cancer medicine will touch every aspect of cancer care-from patient counselling, to cancer diagnosis, tumour classification, treatment and outcome-that demands a new level of in-depth education and collaboration between researchers, cancer specialists, patients and other stakeholders. In this position paper, ESMO sets out the current status in the field of personalised cancer medicine and addresses issues and challenges for the medical oncology community.

Statistics

Citations

27 citations in Web of Science®
35 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

33 downloads since deposited on 17 Jul 2014
22 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Oncology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:20 June 2014
Deposited On:17 Jul 2014 12:44
Last Modified:05 Apr 2016 17:58
Publisher:Oxford University Press
ISSN:0923-7534
Additional Information:This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Annals of Oncology following peer review. The definitive publisher-authenticated version Ann. Onc. 2014 : mdu217v1-mdu217 is available online at: http://dx.doi.org/10.1093/annonc/mdu217
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1093/annonc/mdu217
PubMed ID:24950979

Download

Preview Icon on Download
Preview
Content: Accepted Version
Filetype: PDF
Size: 215kB
View at publisher